share_log

ST吉药(300108.SZ)：公司股票交易被实行退市风险警示 股票停牌

ST Pharmaceutical (300108.SZ): The company's stock trading was subject to delisting risk warning, stock trading suspended

Gelonghui Finance ·  Apr 28 09:12

Gelonghui announced on April 28 | ST Jiyao (300108.SZ). After an audit, the company's net assets at the end of the 2023 period were negative. It touches upon the provisions of section 10.3.1 (2) of the “Shenzhen Stock Exchange GEM Stock Listing Rules”: “The net assets at the end of the audited fiscal year were negative, or the net assets at the end of the most recent fiscal year were negative after retroactive restatement”. The company's 2023 audit agency, a certified public accounting firm (special general partnership), issued an audit report that was unable to express an opinion on the company's 2023 financial statements, touching on the provisions of section 10.3.1 (3) of the “Shenzhen Stock Exchange GEM Stock Listing Rules”: Listed companies “have issued an audit report where the financial accounting report for the most recent fiscal year is unable to express an opinion or negative opinion”, and their stock transactions will be subject to a delisting risk warning. In view of the above two situations, the company's stock was simultaneously subject to a delisting risk warning. After the disclosure of the 2023 annual report, trading of the company's shares was suspended for 1 day on April 29, 2024. Since April 30, 2024, the Shenzhen Stock Exchange implemented a delisting risk warning. The stock abbreviation was changed from “ST Pharmaceutical” to “*ST Pharmaceutical”.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment